Fulcrum Therapeutics Common Stock

The latest common stock for FULC is $76K as of June 2026. That compares with $54K in the prior-year period — up 40.7% year over year. Investors often review this figure alongside Fulcrum Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FULC's common stock moved from $54K to $76K — a 40.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fulcrum Therapeutics's operating scale or balance-sheet position.

A common stock figure of $76K for FULC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting FULC's common stock ($76K), review year-over-year change from $54K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Fulcrum Therapeutics's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.